Surgery in recurrent epithelial ovarian cancer: Benefits on survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction

Journal of Surgical Oncology

Volumn 101, Issue 3, 2010, Pages 244-250

  Tian, Wen Juan ^a   Jiang, Rong ^a   Cheng, Xi ^a   Tang, Jie ^a   Xing, Yan ^b   Zang, Rong Yu ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ovarian cancer; Recurrence; Secondary cytoreduction; Surgery; Survival

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; PACLITAXEL;

ADULT; AGED; ARTICLE; ASCITES; BACTERIAL INFECTION; BLEEDING; CANCER PATIENT; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTOVAGINAL FISTULA; CYTOREDUCTIVE SURGERY; DATA BASE; FEMALE; FISTULA; GASTROINTESTINAL INFECTION; HEMATOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MYCOSIS; OVARY CANCER; PELVIC HEMATOMA; PRIORITY JOURNAL; RECURRENT CANCER; URETEROVAGINAL FISTULA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 77249161759     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21491     Document Type: Article

References (22)

1. Omura GA, Bundy BN, Berek JS, et al.: Randomized trial of cyclophosphamide plus cisplatin with or without doxirubicin in ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 1989;7:457-465.
2. Hoskins WJ, McGuir WP, Brady MF, et al.: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-979.
3. Chi DS, Eisenhauer EL, Lang J, et al.: What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103:559-564.
4. Winter WE, Maxwell GL, Tian C, et al.: Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621-3627.
5. Berek JS, Hacker NF, Lagasse LD, et al.: Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 1983;61:189-193.
6. Zang RY, Li ZT, Tang J, et al.: Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits? Cancer 2004;100:1152-1161.
7. Munkarah A, Levenback C, Wolf JK, et al.: Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 2001;81:237-241.
8. Harter P, du Bois A, Hahmann M, et al.: Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Oncol 2006;3:1702-1710.
9. Glehen O, Osinsky D, Cotte E, et al.: Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: Morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003;10:863-869.
10. Janicke F, Holscher M, KuhnW, et al.: Radical surgical-proceduar improves survival-time in patients with recurrent ovarian-cancer. Cancer 1992;70:2129-2136.
11. Scarabelli C, Gallo A, Campagnutta E, et al.: Splenectomy during primary and secondary cytoreductive surgery for epithelial ovarian carcinoma. Int J Gynecol Cancer 1998;8:215-221.
12. Landoni F, Pellegrino A, Cormio G, et al.: Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look Laparotomy. Acta Obstet Gynecol Scand 1998;77:233-237.
13. Eisenkop SM, Friedman RL, Spirtos NM: The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88:144-153.
14. Cormio G, di Vagno G, Cazzolla A, et al.: Surgical treatment of recurrent ovarian cancer: Report of 21 cases and a review of the literature. Eur J Obstet Gynecol Reprod Biol 1999;86:185-188.
15. Tay EH, Grant PT, Gebski V, et al.: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 2002;99:1008-1013.
16. Onda T, Yoshikawa H, Yasugi T, et al.: Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: Proposal for patients selection. Br J Cancer 2005;92:1026-1032.
17. Gronlund B, Lundvall L, Christensen IJ, et al.: Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol 2005;31:67-73.
18. Ayhan A, Gultekin M, Taskiran C, et al.: The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol 2006;194:49-56.
19. Benedetti Panici P, De Vivo A, Bellati F, et al.: Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 2007;14:1136-1142.
20. Salani R, Santillan A, Zahurak ML, et al.: Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: Analysis of prognostic factors and survival outcome. Cancer 2007;109:685-691.
21. Oksefjell H, Sandstad B, Tropé C: The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 2009;20:286-293.
22. Chi DS, McCaughty K, Diaz JP, et al.: Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006;106:1933-1939.